TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05538091
Drug: Vismodegib
Normalized name: Vismodegib
DrugBank: Vismodegib (DB08828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A small-molecule SMO inhibitor designed to specifically target the hedgehog pathway, a known driver of BCC. It systemically inhibits hedgehog pathway signaling. Following mutation, SMO is released from the inhibitory effect of PTCH and moves to the cell surface, activating GLI. GLI travels to the nucleus and initiates transcription of target genes that regulate basal cell growth and proliferation.
Study: NCT05538091
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab is a humanized monoclonal antibody immune checkpoint inhibitor that selectively binds to PD-L1 to stop the interaction between PD-1 and B7.1 (CD80 receptors). The antibody still allows interaction between PD-L2 and PD-1.
Study: NCT06255379
Drug: Fuquinitinib+Tegafur Gimeracil Oteracil
Normalized name: tegafur
DrugBank: Oteracil (DB03209)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Fuquinitinib:5 mg once daily, 2 weeks on/1 week off,q3w; Tegafur Gimeracil Oteracil:BSA(body surface area)\< 1.2m2,40mg/m2,p.o,bid,2 weeks on/1 week off,q3w; 1.2m2 \< BSA （body surface area）\< 1.5m2,50mg/m2,p.o,bid,2 weeks on/1 week off,q3w;BSA（body surface area） \>1.5m2,60mg/m2,p.o,bid,2 weeks on/1 week off,q3w;
Study: NCT05706038
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab is a fully human, high-affinity, recombinant anti-tumor necrosis factor (TNF) alpha monoclonal antibody used to treat rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, Crohn disease, ulcerative colitis, etc.~Adalimumab is a fully human, high-affinity, recombinant immunoglobulin G (IgG) anti-TNF alpha monoclonal antibody. It is a molecule comprising 1330 amino acids and has a molecular weight of approximately 148 kDa.\[4\] It inhibits the binding of TNF alpha (both soluble and membrane-bound) to its receptor. Specifically, it inhibits TNF alpha's interaction with p55 (TNFR1) and p75 (TNFR2) cell surface TNF receptors, which in turn interferes with cytokine-driven inflammatory processes. It is identical in structure and function to the naturally occurring human IgG1 and thus has high selectivity for TNF alpha and has low immunogenic potential.
Study: NCT06507904
Drug: Osivelotor
Normalized name: Osivelotor
DrugBank: Osivelotor (DB18071)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A medicine to treat sickle cell disease.
Study: NCT05470816
Drug: Tranexamic Acid 100Mg/ml Inj Vial 10ml
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention is from the Tranexamic acid to Reduce Infection after Gastrointestinal Surgery: the TRIGS Trial. A multicentre, pragmatic, double-blind, randomised clinical trial will compare the incidence of surgical site infection and red cell transfusion requirements after IV tranexamic acid and placebo in patients undergoing gastrointestinal surgery
Study: NCT05138159
Drug: Donafenib
Normalized name: DONAFENIB
DrugBank: CM-4307 (DB15414)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donafenib: 200mg po bid.
Study: NCT05138159
Drug: S1
Normalized name: LS11
DrugBank: LS11 (DB05918)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 capsule: According to the body surface area \<1.25m2 40mg/d, 1.25 \~ 1.5 m2 50 mg/d, \> 1.5m2 60mg/d po bid, taking 14 days, stopping for 7 days, 21 days for 1 cycle.
Study: NCT06537011
Drug: AK112
Normalized name: IMMUNOGLOBULIN G1 (240-ALANINE,241-ALANINE), ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR A) (HUMAN-MUS MUSCULUS MONOCLONAL AK112 .GAMMA.1-CHAIN) FUSION PROTEIN WITH PEPTIDE LINKER (GGGS)4 FUSION PROTEIN WITH IMMUNOGLOBULIN ANTI-(HUMAN PROGRAMMED CELL
DrugBank: Ivonescimab (DB18931)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. The patients are given AK112 combined with AP regimen every 3 weeks for 3 cycles before operation.~2. After the neoadjuvant therapy ,the patients will be assessed and be commanded surgery.~3.4-6 weeks after the surgery, the patients will be given chemoradiotherapy or radiotherapy alone decided on the conditon after surgery.~4.The participants will receive AK112 for 14 cycles after surgery.
Study: NCT05964114
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Initial dosing based on (a combinations of) pharmacokinetic models tailored to the individual patient. Dose adjustment starting dose (within registered dosing range).
Study: NCT05236972
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab 200mg iv drip Q3W
Study: NCT05236972
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 130 mg/m² iv drip over 2 hours on day 1, repeated every 21 days.
Study: NCT06649227
Drug: CAR-T cell therapy
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cyclophosphamide and fludarabin conditioning , followed by a target dose of 1 x 10exp6 of autologous, genetically modified, anti-CD19 CAR-T cells per kg of body weight.
Study: NCT06233877
Drug: G-GLIP plus Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: G-FLIP: Gemcitabine, Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin plus Mitomycin C
Study: NCT05893069
Drug: Oxandrolone
Normalized name: Oxandrolone
DrugBank: Oxandrolone (DB00621)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral oxandrolone for 12 weeks
Study: NCT01476163
Drug: migalastat HCl
Normalized name: migalastat HCl
DrugBank: Migalastat (DB05018)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 150 mg capsule taken every other day by mouth. An inactive reminder capsule may be provided to take on the days in between migalastat HCl
Study: NCT05731440
Drug: 18F-Fluselenamyl
Normalized name: (18F)-Fluoride
DrugBank: Amyl acetate (DB15927)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single intravenous bolus injection of 10 mCi ± 20% of the investigational radiotracer 18F-Fluselenamyl and will undergo an 18F-Fluselenamyl PET/CT scan.
Study: NCT05675748
Drug: Azvudine
Normalized name: Azvudine
DrugBank: Azvudine (DB16407)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azvudine tablets are taken orally 5mg daily for a maximum of 14 days
Study: NCT01822951
Drug: Cerebrolysin
Normalized name: cerebrolysin
DrugBank: Cerebrolysin (DB16599)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous medication is given in three treatment courses (TC). Each treatment course lasts for two weeks and consists of 10 infusions (5 infusions weekly). The first treatment course (TC 1) will be in Week 1 and 2, second treatment course (TC 2) will be repeated during Week 9 and 10 and third treatment course (TC 3) during Week 19 and 20.~Placebo for donepezil:1 tablet per day from TC 1 Day 1 on and 2 tablets per day from Visit 3 - Visit 5, p.o.
Study: NCT01822951
Drug: Donepezil
Normalized name: Donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-10 mg donepezil: 1x5 mg donepezil as 1 tablet per day from TC 1 Day 1 on and 2x5 mg donepezil as 2 tablets from Visit 3- Visit 5, p.o.~Intravenous medication is given in three treatment courses (TC). Each treatment course lasts for two weeks and consists of 10 infusions (5 infusions weekly). The first treatment course (TC 1) will be in Week 1 and 2, second treatment course (TC 2) will be repeated during Week 9 and 10 and third treatment course (TC 3) during Week 19 and 20.
Study: NCT06401343
Drug: Empagliflozin 10 MG
Normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants randomized to the study group will received Empagliflozin 10mg q.d. for 12 months.
Study: NCT05156645
Drug: SCTA01 and SCTA01C
Normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diluted by 0.9% normal saline
Study: NCT05502991
Drug: Tislelizumab plus Bevacizumab
Normalized name: Tislelizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200mg sintilimab plus 3mg/kg bevacizumab every 3 weeks
Study: NCT05949541
Drug: Everolimus 10 mg
Normalized name: everolimus 10 MG
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus is a kind of mTOR inhibitor which has been approved to use in several kinds of cancers, especially in metastatic breast cancer.
Study: NCT05949541
Drug: CDK4/6 Inhibitor SHR6390
Normalized name: Cdk4/6 inhibitor shr6390
DrugBank: Dalpiciclib (DB17456)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalpiciclib (SHR6390) is a kind of CDK4/6 inhibitor that has demonstrated tolerability and preliminary clinical activity in patients with heavily pretreated hormone receptor-positive, HER2-negative advanced breast cancer.
Study: NCT05949541
Drug: Aromatase inhibitor and Fulvestrant combined with CDK4/6 inhibitors
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Endocrine therapy combined with CDK4/6 inhibitors is the standard first-line therapy for advanced luminal breast cancer. Investigators choose endocrine therapy including Letrozole, Anastrozole, Exemestane, and Fulvestrant. Postmenopausal participants should use Goserelin.
Study: NCT06509893
Drug: aspirin 80 mg and clopidogrel 75 mg daily
Normalized name: clopidogrel 75 MG
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: post PCI patients received these two drugs as dual antiplatelet regimen
Study: NCT06509893
Drug: Ticagrelor 90 MG
Normalized name: ticagrelor 90 MG
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Post PCI patients receive Ticagrelor 90 mg two times daily as single potent antiplatelet
Study: NCT05771402
Drug: Anti-PD-1 antibody
Normalized name: Monoclonal antibody anti-SSEA-1
DrugBank: Fanolesomab (DB14211)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once/two or three weeks, dose lower than the dose used in cancer patients, subcutaneous/intravenous injection
Study: NCT05771402
Drug: Peg-IFNα
Normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once/week, 180μg/time, subcutaneous injection
Study: NCT04865939
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravesical gemcitabine instilled into bladder during surgery (drained prior to entry into bladder).
Study: NCT06730308
Drug: Concurrent chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: weekly albumin-bound paclitaxel (50 mg/m²) and cisplatin (25 mg/m²)
Study: NCT06730308
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone 2mg/kg, qd, concurrent with radiotherapy
Study: NCT05629806
Drug: Metformin plus pioglitazone
Normalized name: metformin / pioglitazone
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: After the screening period, eligible subjects were admitted to two tablets of fixed mixture of metformin plus pioglitazone (15mg pioglitazone plus 500mg metformin) for 12 weeks. Then the subjects were titrated onto the alternative treatment of 50mg acarbose three times daily for 12 weeks. During this timeframe, all patients were instructed to monitor their blood glucose fluctuations with a FreeStyle Libre Pro Sensor (FGM system) before and after the study and the time point of drug replacement.
Study: NCT05629806
Drug: Acarbose
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After the screening period, eligible subjects were admitted to 50mg acarbose three times daily for 12 weeks. Then the subjects were titrated onto the alternative treatment of two tablets of fixed mixture of metformin plus pioglitazone (15mg pioglitazone plus 500mg metformin) for 12 weeks. During this timeframe, all patients were instructed to monitor their blood glucose fluctuations with a FreeStyle Libre Pro Sensor (FGM system) before and after the study and the time point of drug replacement.
Study: NCT06303128
Drug: Amoxicillin 250 MG
Normalized name: amoxicillin 250 MG
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liquid amoxicillin 250mg PO
Study: NCT06303128
Drug: Amoxicillin 62.5mg
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given first in two-dose group, liquid amoxicillin 62.5mg PO
Study: NCT06303128
Drug: Amoxicillin 187.5mg
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given second in two-dose group, liquid amoxicillin 187.5mg PO
Study: NCT06731153
Drug: Ivarmacitinib
Normalized name: Ivarmacitinib
DrugBank: Ivarmacitinib (DB16756)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a selective Janus kinase 1 inhibitor
Study: NCT06731153
Drug: Camrelizumab (SHR-1210)
Normalized name: Ocrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: a humanised anti-programmed death-1 (anti PD-1) antibody
Study: NCT06731153
Drug: Eribulin
Normalized name: Eribulin
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eribulin is an anticancer drug approved for treatment of metastatic breast cancer. This drug is a synthetic derivative from Japanese marine sponge Halichondria okadai. It acts by interfering with the microtubular growth ultimately leading to apoptosis after prolonged mitotic blockage.
Study: NCT04800614
Drug: sitravatinib
Normalized name: Sitravatinib
DrugBank: Sitravatinib (DB15036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg sitravatinib on Day 1 of each of 3 periods
Study: NCT05007145
Drug: PD-1 inhibitor
Normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 Inhibitor 200mg D1 Q3W
Study: NCT05007145
Drug: Albumin-Bound Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 125 mg/m\^2 D1/D8 Q3W
Study: NCT05007145
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m\^2 D1 Q3W
Study: NCT04189133
Drug: Lutropin alfa
Normalized name: Lutropin alfa
DrugBank: Lutropin alfa (DB00044)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: daily increasing dosages of lutropin alfa
Study: NCT04189133
Drug: Human chorionic gonadotropin
Normalized name: human chorionic gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: human chorionic gonadotropin increasing administration
Study: NCT05595408
Drug: adjuvant immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: immunotherapy for one year
Study: NCT05313750
Drug: anti-infective therapy sitafloxacin
Normalized name: gentian violet
DrugBank: Sitafloxacin (DB13261)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: anti-infective therapy
Study: NCT05313750
Drug: anti-infective therapy levofloxacin
Normalized name: gentian violet
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: anti-infective therapy
Study: NCT06120673
Drug: Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive an intravenous infusion of 1,000mg Obinutuzumab at Weeks 0, 2, 24 and 26.~Prior to the administration of obinutuzumab, the participant will receive pre-medications consisting of all three:~* IV methylprednisolone 80 mg,~* Paracetamol 1,000 mg orally,~* Either cetirizine 10 mg orally or diphenhydramine 50 mg orally. These pre-medications must be completed between 30 to 60 minutes prior to the obinutuzumab infusion.
Study: NCT04865211
Drug: Liposomal bupivacaine
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Use of liposomal bupivicaine as intraoperative local anesthesia
Study: NCT04742309
Drug: Pecs-2 block (single injection)
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For Pecs-2 blocks, the needle will be advanced to the tissue plane between the pectoralis major and minor muscles at the vicinity of the pectoral branch of the acromiothoracic artery where 10 mL of local anesthetic will be deposited. In a similar manner, 20 mL will be deposited at the level of the third rib above the serratus anterior muscle with the intent of spreading injectate to the axilla. The study fluid will be ropivacaine 0.3% with epinephrine.
Study: NCT04742309
Drug: Paravertebral block (single injection)
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For paravertebral blocks, ropivacaine 0.5% (with epinephrine) 9 mL will be administered at each of two levels per side: the T3 and T5 levels for sides without axillary involvement; and at the T2 and T4 level for sides with axillary involvement.
Study: NCT05320068
Drug: Oral Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A blinded capsule that contains 125mg of vancomycin every 6 hours during 10 days.
Study: NCT04865211
Drug: Bupivacaine Injection
Normalized name: bupivacaine Injection
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Use of bupivicaine as intraoperative local anesthesia
Study: NCT06125340
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose amoxicillin (approved by Health Canada) to be given x 5 days.
Study: NCT05693545
Drug: phenoxymethyl penicillin
Normalized name: Phenoxymethyl Penicillin
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylaxis
Study: NCT06304740
Drug: IMG-007
Normalized name: IMG-7289
DrugBank: IMG-7289 (DB15126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of IMG-007
Study: NCT05649345
Drug: TR64
Normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: TR64 tablets will be given daily for 28 days in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons.
Study: NCT05737433
Drug: [14C]-rencofilstat 225mg
DrugBank: Rencofilstat (DB18246)
Approvals — FDA: no, EMA: no, PMDA: no
Description: radio-labelled 225mg oral dose of rencofilstat
Study: NCT06731595
Drug: Colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: colchicine 0.6mg oral twice daily for 7 days
Study: NCT04775550
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous, dosage per protocol, dose days vary per cycle. Cycle =28 days
Study: NCT04775550
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous, dosage per protocol, dose days vary per cycle. Cycle =28 days
Study: NCT04775550
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral, dosage per protocol, days 1-21 per cycle
Study: NCT04775550
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral, dosage per protocol, dose days vary per cycle. Cycle =28 days
Study: NCT02865109
Drug: Nusinersen
Normalized name: Nusinersen
DrugBank: Nusinersen (DB13161)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered by intrathecal injection
Study: NCT05507372
Drug: Pimozide 1 MG
Normalized name: pimozide 1 MG
DrugBank: Pimozide (DB01100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dopamine Receptor Antagonist - Oral Pimozide
Study: NCT05020704
Drug: Empagliflozin 10 MG
Normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: SGLT2inhibitor
Study: NCT04247906
Drug: Narsoplimab
Normalized name: Narsoplimab
DrugBank: Narsoplimab (DB16418)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05341323
Drug: Ketamine.
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peritonsillar infiltration of ketamine
Study: NCT04944836
Drug: Clomiphene Citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients will receive non-labeled pills identical in appearance from our pharmacy, to be taking once every other day. In the study group, these will contain 50 mg of clomiphene citrate. In the control group, these will be placebo. These will be taken every other day for seven months beginning four weeks prior to surgery and extending for six months after surgery. After enrollment patients will be randomized. Patient will be assigned to the 2 groups using a permuted block randomization scheme with blocks of size 2, 4, and 6. Prior to initiation of the study opaque sealed envelopes will be prepared and thoroughly shuffled and then used sequentially during the study. These randomization assignments will be available to the pharmacy in a web-based format or by cards in sealed envelopes. A nonparticipant in the study (the pharmacy at our institution) will administer this process.
Study: NCT05571176
Drug: S-ketamine
Normalized name: S-ketamine
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: S-ketamine infusion 0.29 mg/kg/h for 4 hours
Study: NCT04885894
Drug: Zeposia
Normalized name: Zeposia
DrugBank: Ozanimod (DB12612)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants with MS will be divided into two treatment groups: those who will begin to take Zeposia, and those who plan to be begin treatment with high dose oral efficacy medication. The HC group will be free of neurological disease or injury and will be matched to the MS groups for age, gender, and education.
Study: NCT05341323
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: peritonsillar infiltration of Bupivacaine
Study: NCT06034379
Drug: 0.01% atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine is a and anticholinergic medication which can be used for dilation and cycloplegia.
Study: NCT05071716
Drug: Rifaximin SSD
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin Solid Soluble Dispersion Immediate Release Twice Daily
Study: NCT05834036
Drug: Amoxicillin Oral Capsule
Normalized name: amoxicillin Oral Capsule
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin 875mg every 12 hours for 7 days.
Study: NCT05313477
Drug: Ergocalciferol Capsules
Normalized name: Ergocalciferol Capsules
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Depend on initial 25(OH) vitamin D level If \<10ng/mL, 60000U of Ergocalciferol capsules per week If 10-19.9ng/mL, 40000U of Ergocalciferol capsules per week If \>20 ng/mL, 20000U of Ergocalciferol capsule per week